PortugalPortugal

Chiltern goes Portugal

19.08.2008

Lisbon – The international contract research organisation Chiltern sees potential for growth in Portugal. In May, it opened a new office in Lisbon that will be managed by Ricardo Diaz. Over the last two years, numbers of clinical trials have increased in the country.

PortugalPortugal

02.12.2011

Lisbon – Genetically modified organisms (GMOs) are gaining ground in southwestern Europe. According to the European Association for Bioindustries (EuropaBio), Portuguese farmers planted nearly 60% more genetically modified maize...

PortugalPortugal

07.10.2011

Lisbon – In the southwest of Europe, GMOs are gaining ground. According to the European Association for BioIndustries EuropaBio, Portuguese farmers have grown nearly 60% more genetically modified (GM) maize this year compared to...

PortugalPortugal

11.08.2011

Lisbon – According to a report published by business intelligence provider Espicom, the future for biopharma on the westernmost tip of Europe looks anything but sunny. Its analysts predict that by 2016, the pharmaceuticals market...

PortugalPortugal

08.03.2010

Lisbon – Portugal’s “Fundação para a Ciência e Tecnologia” (FCT) is to channel funding into collaborations between Portuguese and Indian life science companies and research within the networking pilot programme “New Indigo”...

PortugalPortugal

14.09.2009

Coimbra/San Francisco/Munster – Portuguese and US researchers have discovered a new factor that determines whether an embryonic stem cell (ESC) will remain pluripotent or not. After the team under Miguel and Joao Ramalho-Santos...

PortugalPortugal

12.07.2009

Madrid –The Spanish Ministry of Health is investing in future biotech treatments. In July, it signed a EUR60m contract over a recombinantly manufactured flu vaccine developed by Rockville-based Novavax. In Phase II trials, the...

09.05.2009

Lisbon/New York - A Portuguese-US research team has discovered a new molecular mechanism that enables gamma herpes viruses to chronically infect patients. Gamma herpes viruses infect white blood cells (B- or T-lymphocytes)...

PortugalPortugal

21.02.2009

Lisbon – Portugal’s Bial SA has granted American company Sepracor the exclusive rights to develop and commercialise eslicarbazepine in the United States and Canada. Bial will receive US$57m up front.

Displaying results 1 to 10 out of 37

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-portugal/article/chiltern-goes-portugal.html

Product of the week

Products

Events

All Events

Current issue

All issues